Amahitamo meza yo kuvura isesemi no kuruka bitewe na chimiotherapie (CINV). Isesemi no kuruka bitewe na chimiotherapie (CINV) ni imwe mu ngaruka mbi zitinywa cyane ku barwayi bavurwa kanseri, bigira ingaruka zikomeye ku kubahiriza ubuvuzi n'imibereho myiza. Nk'ikinyejana gishya cy'imiti irwanya NK1 receptor, Fosaprepitant Dimeglumine, ifite imiterere yayo ya farumasi yo guhitamo neza no gukunda cyane, ishobora guhagarika cyane inzira yo kuruka iterwa n'ikinyabutabire P.
Amakuru y’ubuvuzi yemeza ko uyu muti ugira ingaruka nziza ku isesemi ikabije kandi itinze no kuruka biterwa na chemotherapy ivura indwara ziterwa n’indwara ziterwa n’imiti ivura indwara ziterwa n’imiti (HEC) na chemotherapy ivura indwara ziterwa n’imiti (MEC) mu rugero ruciriritse. Gutanga dose imwe bishobora gutuma habaho kurwanya indwara ziterwa n’imiti ikoreshwa igihe kirekire kandi bikihanganira indwara. Iyo bihujwe n’imiti irwanya 5-HT3 receptor antagonists na dexamethasone, byubaka uburyo bwo kurinda CINV bwuzuye kandi bukora neza.
Kuva ku buryo bworoshye bwo gutanga imiti kugeza ku buryo ihamye bwo kuyikoresha, Fosaprepitant Dimeglumine itanga amahitamo meza yo gukora mu buvuzi, ifasha abarwayi kunyura mu nzira ya chimiotherapie neza kandi bigatuma ubuvuzi bwa kanseri burushaho kuba bwiza.
Igihe cyo kohereza: Ukuboza-09-2025
